Trial Profile
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Brain metastases; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 20 Aug 2013 New trial record